Metrics to compare | FLUIC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFLUICPeersSector | |
|---|---|---|---|---|
P/E Ratio | −18.3x | 30.3x | −0.4x | |
PEG Ratio | −0.23 | 0.18 | 0.00 | |
Price/Book | 3.0x | 2.6x | 2.6x | |
Price / LTM Sales | 2.1x | 4.6x | 2.9x | |
Upside (Analyst Target) | - | 0.0% | 58.0% | |
Fair Value Upside | Unlock | −2.7% | 9.5% | Unlock |
Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch clamp recording configuration. It also provides Biopixlar, a 3D single-cell bioprinting platform that produces single cell arrays to organoids and complex tissues; Nexocyte, a platform for universal tissue production; and Biopixlar AER, a single-cell bioprinting platform that fits into a biosafety cabinet. Fluicell AB (publ) was incorporated in 2012 and is based in Mölndal, Sweden.